Greater than the sum of its parts: A novel psychiatric multimorbidity metric applied to rare disease
- 1Rutgers University
Abstract
Importance: Rare genetic syndromes are often drivers of complex multimorbidity. However, current methods consider multimorbidity as the sum of chronic diagnoses, which does not account for subthreshold impairment. Objective: To develop a quantitative multimorbidity score (MMS) for rare genetic syndromes that summarizes the neurodevelopmental and psychiatric multimorbidity landscape, including subthreshold symptoms, using 3q29 deletion and 3q29 duplication syndromes as hallmark examples. Design: We developed a multimorbidity metric and applied it to cross-sectional data. Remote phenotyping from 2023-2026. In-person phenotyping from 2017-2020. Setting: Remote phenotyping conducted at Rutgers University. In-person phenotyping conducted at Emory University. Participants: Participants were 6 years of age and older. 3q29del and 3q29dup recruited from the 3q29 registry and direct referrals and contacts. Syndrome status confirmed by genetic report review. Typically developing controls recruited from community sources and ResearchMatch. Main Outcomes and Measures: We developed a quantitative MMS across five distinct domains of functioning, operationalized as the sum of z-scores across six standardized assessments. The MMS was calculated for each study participant and compared across groups. Within 3q29del, we evaluated the relationship between MMSs and Vineland-3 adaptive behavior. Results: 96 individuals with 3q29del (52.08% male, 18.01+/-11.47 years old), 28 individuals with 3q29dup (50.00% male, 20.82+/-13.64 years old), and 53 controls (41.51% male, 17.77+/-10.74 years old) were included. 3q29del and 3q29dup participants had significantly lower MMS scores compared to controls (3q29del mean=-8.22+/-4.67, 3q29dup mean=-6.47+/-4.66, control mean=1.36+/-2.35, 3q29del p<2E-16, 3q29dup p=4.89E-16). Within 3q29del, subjects with more severe multimorbidity had greater impairment in adaptive behavior (R2=0.589, p<2E-16). The quantitative MMS is more highly correlated with adaptive behavior than traditional diagnosis-based multimorbidity metrics (quantitative MMS R2=0.589, diagnosis-based multimorbidity R2=0.447). In a subset of 24 3q29del participants with longitudinal data (58.33% male, 13.17+/-9.08 years old at first evaluation, average time to follow up=5.17+/-0.87 years), the MMS is stable over time (R2=0.858, p=8.34E-8). Conclusions and Relevance: Our novel quantitative MMS is an improved metric for measuring psychiatric multimorbidity in high-risk populations, and accounts for the impact of subthreshold impairments. When applied to 3q29del and 3q29dup, it quantifies the individual burden of multimorbidity, is stable over time, and is associated with clinical outcome measures.
Related
- Phenotypic heterogeneity in pediatric pituitary stalk interruption syndrome: greater disease burden in the metabolic-onset phenotype
- Multimorbidity, Polypharmacy, and Periodontal Disease Burden in a University Dental Setting: A Cross-Sectional Study
- Physical Frailty Accelerates Multimorbidity Accumulation Across Distinct Disease Patterns
- Functional organization of multimorbidity links chronic disease incidence to shared genetic architecture
- Greater and Clinically Meaningful Improvement in Health-Related Quality of Life After Device-Aided Therapy in Younger Patients Earlier Within Advanced Parkinson’s Disease: Real-World Evidence from the DATs-PD GETM Spanish Registry
BibTeX
@misc{pollak2026greater,
title = {{Greater than the sum of its parts: A novel psychiatric multimorbidity metric applied to rare disease}},
author = {R. M. Pollak and E. Sefik and C. Klaiman and D. V. Bishop and M. K. Harner and A. Khan and J. R. Purcell and M. Wheeler and T. Irving and S. Pulver and J. F. Cubells and E. F. Walker and M. M. Murphy and J. G. Mulle},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.05.26367370},
url = {https://www.medrxiv.org/content/10.64898/2026.11.05.26367370v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Greater than the sum of its parts: A novel psychiatric multimorbidity metric applied to rare disease
AU - R. M. Pollak
AU - E. Sefik
AU - C. Klaiman
AU - D. V. Bishop
AU - M. K. Harner
AU - A. Khan
AU - J. R. Purcell
AU - M. Wheeler
AU - T. Irving
AU - S. Pulver
AU - J. F. Cubells
AU - E. F. Walker
AU - M. M. Murphy
AU - J. G. Mulle
PY - 2026
DA - 2026/11/05
PB - medRxiv
DO - 10.64898/2026.11.05.26367370
UR - https://www.medrxiv.org/content/10.64898/2026.11.05.26367370v1
AB - Importance: Rare genetic syndromes are often drivers of complex multimorbidity. However, current methods consider multimorbidity as the sum of chronic diagnoses, which does not account for subthreshold impairment. Objective: To develop a quantitative multimorbidity score (MMS) for rare genetic syndromes that summarizes the neurodevelopmental and psychiatric multimorbidity landscape, including subthreshold symptoms, using 3q29 deletion and 3q29 duplication syndromes as hallmark examples. Design: We developed a multimorbidity metric and applied it to cross-sectional data. Remote phenotyping from 2023-2026. In-person phenotyping from 2017-2020. Setting: Remote phenotyping conducted at Rutgers University. In-person phenotyping conducted at Emory University. Participants: Participants were 6 years of age and older. 3q29del and 3q29dup recruited from the 3q29 registry and direct referrals and contacts. Syndrome status confirmed by genetic report review. Typically developing controls recruited from community sources and ResearchMatch. Main Outcomes and Measures: We developed a quantitative MMS across five distinct domains of functioning, operationalized as the sum of z-scores across six standardized assessments. The MMS was calculated for each study participant and compared across groups. Within 3q29del, we evaluated the relationship between MMSs and Vineland-3 adaptive behavior. Results: 96 individuals with 3q29del (52.08% male, 18.01+/-11.47 years old), 28 individuals with 3q29dup (50.00% male, 20.82+/-13.64 years old), and 53 controls (41.51% male, 17.77+/-10.74 years old) were included. 3q29del and 3q29dup participants had significantly lower MMS scores compared to controls (3q29del mean=-8.22+/-4.67, 3q29dup mean=-6.47+/-4.66, control mean=1.36+/-2.35, 3q29del p<2E-16, 3q29dup p=4.89E-16). Within 3q29del, subjects with more severe multimorbidity had greater impairment in adaptive behavior (R2=0.589, p<2E-16). The quantitative MMS is more highly correlated with adaptive behavior than traditional diagnosis-based multimorbidity metrics (quantitative MMS R2=0.589, diagnosis-based multimorbidity R2=0.447). In a subset of 24 3q29del participants with longitudinal data (58.33% male, 13.17+/-9.08 years old at first evaluation, average time to follow up=5.17+/-0.87 years), the MMS is stable over time (R2=0.858, p=8.34E-8). Conclusions and Relevance: Our novel quantitative MMS is an improved metric for measuring psychiatric multimorbidity in high-risk populations, and accounts for the impact of subthreshold impairments. When applied to 3q29del and 3q29dup, it quantifies the individual burden of multimorbidity, is stable over time, and is associated with clinical outcome measures.
ER -